Michael T Flavin

Bio

Michael T. Flavin, Ph.D., has 28 years of experience in the life sciences industry having successfully started and built two drug discovery and development companies. Dr. Flavin is currently the Chief Executive Officer of Shamrock Structures, LLC, a structural biology company owned by Flavin Ventures, LLLC. As Chief Executive Officer and Chairman of Advanced Life Sciences, Inc. since 2002, he led the company’s acquisition and scientific development of Restanza (cethromycin), a novel oral antibiotic. Prior to this date, he was the founder, Chief Executive Officer and Chairman of MediChem Life Sciences, Inc., a drug discovery technology and services company. Dr. Flavin took MediChem from start-up in 1987 through many stages of development including the completion of MediChem's private placement, the acquisition and integration of ThermoGen and Emerald Biostructures as MediChem subsidiaries and MediChem's initial public offering in October 2000. MediChem was acquired in March 2002 by deCOD E genetics. Dr. Flavin was the Chief Executive Officer of MediChem, as a subsidiary of deCODE, through May 2002. Dr. Flavin received a B.S. in Chemistry from the University of Notre Dame, a Ph.D. in Medicinal Chemistry from the University of Illinois at Chicago and he completed a postdoctoral fellowship at Harvard University in organic chemistry. Dr. Flavin is a board member for iBIO and Lewis University, is an Adjunct Professor for the Department of Medicinal Chemistry & Pharmacognosy at the University of Illinois at Chicago and a guest lecturer at the University of Chicago Booth Graduate School of Business in the area of biotechnology entrepreneurship .